C3 glomerulonephritis in a patient treated with anti–PD-1 antibody

Abstract : Immune checkpoint inhibitors (ICIs) have dramati-cally transformed the treatment of solid tumors. ICIsinduce an immune response against tumoral cells as aresult of the removal of T-cell inhibition [1]. The logicalcounterpart of turning off T-cell inhibitory mechanismsis the onset of immune-related adverse events (irAEs)that affect different organs. Although the most frequentrenal irAE is acute interstitial nephritis [2], we report afirst case of C3 glomerulonephritis (GN) associated withthe use of an antieProgrammed Cell Death 1 (PD-1)humanised antibody.